Here’s how we can make clinical trials more inclusive

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Since COVID-19 made its way to the United States, we have seen a stream of worrying news of the pandemic’s impact on cancer care in the U.S., including 9.4 million missed screenings1 for just about all forms of cancer. While screening rates rebounded in the fall of 20202, there’s a growing concern from oncologists that screenings haven’t returned to pre-pandemic levels for everyone. 

And the data are compelling. From September to December 2020, for example, fewer Black and Hispanic women2 had mammograms than in the three months prior to the pandemic. In addition, Black men were 25% less likely3 than their white counterparts to get a prostatectomy during the pandemic. 

There is significant concern among health equity advocates that the pandemic’s ripple effects on cancer care could be sustaining or even deepening widely recognized and reported health disparities for vulnerable communities, including Black, Latinx, and rural Americans.4 Warnings from experts of the pandemic’s impact on cancer disparities necessitate an even greater urgency to further reduce gaps in care.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Jenny Sherak
Senior vice president & President, Specialty Physician Services AmerisourceBergen
Table of Contents

YOU MAY BE INTERESTED IN

NIH announced Jan. 29 that “Basic Experimental Studies Involving Humans,” also called BESH, will no longer be considered clinical trials and will therefore no longer be subject to the requirements under the NIH definition of a clinical trial, including registration and reporting requirements in ClinicalTrials.gov.
Moderna and Merck announced median five-year follow-up data from the phase IIb KEYNOTE-942/mRNA-4157-P201 study, evaluating intismeran autogene (mRNA-4157 or V940), an investigational mRNA-based individualized neoantigen therapy, in combination with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with high-risk melanoma (stage 3/4) following complete resection. 
Patients saw a 35% reduced risk of disease progression or death for Trodelvy (sacituzumab govitecan-hziy) plus Keytruda (pembrolizumab) (n=221) versus standard of care Keytruda plus chemotherapy (n=222), according to the positive phase III ASCENT-04/KEYNOTE-D19 study evaluating the combination of Trodelvy plus Keytruda in first-line PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer. 
Jenny Sherak
Senior vice president & President, Specialty Physician Services AmerisourceBergen

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login